Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
14
pubmed:dateCreated
2008-3-10
pubmed:abstractText
Polypyrrole-Fe3O4 nanospheres were synthesized via an emulsion polymerization method with hyaluronic acid as the surfactant. Hyaluronic acid offers the advantages of biocompatibility, cell adhesive property and the availability of functional groups for attachment of other molecules. The nanospheres were further functionalized with herceptin, and the efficacy of uptake of the functionalized nanospheres by human breast cancer cells was evaluated. It is envisioned that the combination of hyaluronic acid with its cell adhesive property and herceptin would result in high efficacy of internalization of the nanospheres by the cancer cells via a HER-2-mediated endocytosis. Our results showed that this is indeed the case and that the high concentration of herceptin-functionalized magnetic nanospheres in the cancer cells offers great potential in cancer cell targeting and treatment. In addition, the magnetic property of these nanospheres was also critically investigated and the magnetization was found to be affected by the particles' environment. The combination of these cell-targeting magnetic carriers with chemotherapeutic agents will be highly advantageous for the preferential killing of cancer cells in hyperthermia treatment.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-11118047, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-11717318, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-12419746, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-12594741, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-12615732, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-14613984, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-14647448, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-14973048, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-15150302, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-15279897, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-15363548, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-15756027, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-16131220, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-16447039, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-16458110, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-16529418, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-16757022, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-1688187, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-1689212, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-16914581, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-17303515, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-17635517, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-2999773, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-3798106, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-6870820, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-7877976, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-8390537, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-9234965, http://linkedlifedata.com/resource/pubmed/commentcorrection/18289668-9260565
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
May
pubmed:issn
0142-9612
pubmed:author
pubmed:issnType
Print
pubmed:volume
29
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2270-9
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:18289668-Antibodies, Monoclonal, pubmed-meshheading:18289668-Antibodies, Monoclonal, Humanized, pubmed-meshheading:18289668-Antineoplastic Agents, pubmed-meshheading:18289668-Breast Neoplasms, pubmed-meshheading:18289668-Cell Line, Tumor, pubmed-meshheading:18289668-Cell Survival, pubmed-meshheading:18289668-Dose-Response Relationship, Drug, pubmed-meshheading:18289668-Endocytosis, pubmed-meshheading:18289668-Female, pubmed-meshheading:18289668-Formazans, pubmed-meshheading:18289668-Gene Therapy, pubmed-meshheading:18289668-Humans, pubmed-meshheading:18289668-Light, pubmed-meshheading:18289668-Magnetics, pubmed-meshheading:18289668-Nanospheres, pubmed-meshheading:18289668-Particle Size, pubmed-meshheading:18289668-Receptor, erbB-2, pubmed-meshheading:18289668-Scattering, Radiation, pubmed-meshheading:18289668-Tetrazolium Salts
pubmed:year
2008
pubmed:articleTitle
HER-2-mediated endocytosis of magnetic nanospheres and the implications in cell targeting and particle magnetization.
pubmed:affiliation
Department of Chemical and Biomolecular Engineering, National University of Singapore, Kent Ridge, Singapore 119260.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural